1. European Medicines Evaluation Agency. Guidelines on comparability of medicinal products containing biotechnology-derived proteins as active substance: Quality issues. EMEA/CPMP/BWP/3207/00/Rev 1. (EMEA, London, 2000).
2. European Medicines Evaluation Agency. Guidelines on comparability of medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. EMEA/CPMP/3097 /02/Final (EMEA, London, 2002).
3. Schellekens, H. Trends Biotechnol. 22, 406–410 (2004).
4. Bennet, C.L. et al. N. Eng. J. Med. 351, 1403–1408 (2004).
5. Mossinghoff, G.J. Food Drug Law J. 54, 187–194 (1999).